Fundraising Fox

DurVena

Mission, US · Founded 2020 · Delaware corporation

DurVena is developing a photochemical tissue passivation therapy that treats harvested veins to strengthen tissue and improve long-term vein graft durability. The company targets vascular surgery applications where vein grafts are used for reconstructive procedures.

Founders & leadership

ESEric Schlote
Eric SchloteinChief Executive Officer

Board

RT
Robert ThatcherBoard director
WA
William AustenBoard director

Reported raises · per SEC filings

Form D private placements

$14M disclosed across 1 round · 2024

$14MraisedJan 2025 · 37 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert ThatcherDirector
  • Eric SchloteExecutive Officer, Director
  • William AustenDirector
Offering amount
$16.2M
Amount sold
$14M
First sale
Dec 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Companies competing with DurVena for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does DurVena do?
DurVena is developing a photochemical tissue passivation therapy that treats harvested veins to strengthen tissue and improve long-term vein graft durability. The company targets vascular surgery applications where vein grafts are used for reconstructive procedures.
How much funding has DurVena raised?
DurVena has disclosed $14M raised across 1 round.
Where is DurVena headquartered?
DurVena is headquartered in Mission, US.